HK1211179A1 - Immunostimulatory oligonucleotide multimers - Google Patents
Immunostimulatory oligonucleotide multimersInfo
- Publication number
- HK1211179A1 HK1211179A1 HK15112153.1A HK15112153A HK1211179A1 HK 1211179 A1 HK1211179 A1 HK 1211179A1 HK 15112153 A HK15112153 A HK 15112153A HK 1211179 A1 HK1211179 A1 HK 1211179A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- immunostimulatory oligonucleotide
- oligonucleotide multimers
- multimers
- immunostimulatory
- oligonucleotide
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57998504P | 2004-06-15 | 2004-06-15 | |
US59936204P | 2004-08-06 | 2004-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1211179A1 true HK1211179A1 (en) | 2016-05-20 |
Family
ID=35600219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15112153.1A HK1211179A1 (en) | 2004-06-15 | 2015-12-09 | Immunostimulatory oligonucleotide multimers |
Country Status (20)
Country | Link |
---|---|
US (4) | US20060014713A1 (en) |
EP (2) | EP2901856B1 (en) |
JP (1) | JP4942646B2 (en) |
KR (1) | KR20070028537A (en) |
AU (1) | AU2005257938B2 (en) |
BR (1) | BRPI0512110A (en) |
CA (1) | CA2570786C (en) |
EE (1) | EE200700003A (en) |
ES (1) | ES2645158T3 (en) |
HK (1) | HK1211179A1 (en) |
HR (1) | HRP20070012A2 (en) |
HU (1) | HUE036894T2 (en) |
IL (1) | IL179973A0 (en) |
LV (1) | LV13641B (en) |
MA (1) | MA28976B1 (en) |
MX (1) | MXPA06014915A (en) |
NO (1) | NO20070263L (en) |
NZ (1) | NZ552522A (en) |
RU (1) | RU2007101039A (en) |
WO (1) | WO2006002038A2 (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
JP4663113B2 (en) * | 1997-09-05 | 2011-03-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Use of immunostimulatory oligonucleotides to prevent or reduce antigen-stimulated granulocyte-mediated inflammation |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
KR100917101B1 (en) * | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | Flexible metal laminate and production method thereof |
CA2423487C (en) * | 2000-09-26 | 2015-12-15 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
CN100334228C (en) | 2001-06-21 | 2007-08-29 | 戴纳瓦克斯技术公司 | Cimeric immunomodulatory compounds and methods of using the same |
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
AR040996A1 (en) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US7851453B2 (en) * | 2003-01-16 | 2010-12-14 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
AU2004241093B2 (en) * | 2003-05-16 | 2009-08-27 | Idera Pharmaceuticals, Inc. | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents |
EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
AU2004259204B2 (en) * | 2003-07-15 | 2010-08-19 | Idera Pharmaceuticals, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
CA2540949A1 (en) | 2003-10-30 | 2005-05-12 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
AU2005326144A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
EP2901856B1 (en) * | 2004-06-15 | 2017-08-09 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
US7427405B2 (en) * | 2004-06-15 | 2008-09-23 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
CN101160401A (en) * | 2005-02-24 | 2008-04-09 | 科勒制药集团公司 | Immunostimulatory oligonucleotides |
DK2179737T3 (en) | 2005-07-01 | 2013-11-11 | Index Pharmaceuticals Ab | MODULE RESPONSE ON STEROIDS |
ATE476193T1 (en) | 2005-07-01 | 2010-08-15 | Index Pharmaceuticals Ab | IMMUNO-STIMULATORY PROCEDURE |
AU2006306805A1 (en) | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
US7470674B2 (en) * | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
EP2405002B1 (en) * | 2006-02-15 | 2014-09-24 | AdiuTide Pharmaceuticals GmbH | Compositions and methods for oligonucleotide formulations |
MX2009003398A (en) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity. |
CA2693266C (en) * | 2007-08-01 | 2015-06-30 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
AU2010229835B2 (en) | 2009-03-25 | 2015-01-15 | The Board Of Regents Of The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
KR101898177B1 (en) * | 2013-01-08 | 2018-09-12 | 이데라 파마슈티칼즈, 인코포레이티드 | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
CN105579582A (en) | 2013-07-25 | 2016-05-11 | 埃克西奎雷股份有限公司 | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
JPWO2015108047A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator |
EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
JPWO2015108048A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant and antitumor agent having antitumor activity |
CA2953216C (en) | 2014-06-04 | 2020-12-22 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
ES2908056T3 (en) * | 2014-10-10 | 2022-04-27 | Idera Pharmaceuticals Inc | Cancer treatment by TLR9 agonists with checkpoint inhibitors |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
KR20190096936A (en) | 2016-09-15 | 2019-08-20 | 이데라 파마슈티칼즈, 인코포레이티드 | Immune Modulation with TLR9 Agonists for Cancer Treatment |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
AU2021236059A1 (en) * | 2020-03-09 | 2022-11-03 | Dynavax Technologies Corporation | Shingles vaccines comprising a TLR9 agonist |
US20230072809A1 (en) * | 2020-03-09 | 2023-03-09 | Dynavax Technologies Corporation | Active booster immunization against tetanus, diphtheria and pertussis |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5652355A (en) * | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
TW244371B (en) | 1992-07-23 | 1995-04-01 | Tri Clover Inc | |
US6346614B1 (en) | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
US5912332A (en) | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
CA2423487C (en) * | 2000-09-26 | 2015-12-15 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
DE60142410D1 (en) * | 2000-12-27 | 2010-07-29 | Dynavax Tech Corp | IMMUNOMODULATORY POLYNUCLEOTIDES AND METHOD FOR THE USE THEREOF |
CN100334228C (en) * | 2001-06-21 | 2007-08-29 | 戴纳瓦克斯技术公司 | Cimeric immunomodulatory compounds and methods of using the same |
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
WO2003035836A2 (en) * | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
JP2006516099A (en) * | 2002-12-23 | 2006-06-22 | ダイナバックス テクノロジーズ コーポレイション | Branched immunomodulatory compounds and methods of using the compounds |
US7851453B2 (en) * | 2003-01-16 | 2010-12-14 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
US20050004579A1 (en) | 2003-06-27 | 2005-01-06 | Schneider M. Bret | Computer-assisted manipulation of catheters and guide wires |
AU2004259204B2 (en) * | 2003-07-15 | 2010-08-19 | Idera Pharmaceuticals, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
US7427405B2 (en) * | 2004-06-15 | 2008-09-23 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
EP2901856B1 (en) * | 2004-06-15 | 2017-08-09 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
-
2005
- 2005-06-15 EP EP15153954.1A patent/EP2901856B1/en active Active
- 2005-06-15 NZ NZ552522A patent/NZ552522A/en unknown
- 2005-06-15 CA CA2570786A patent/CA2570786C/en active Active
- 2005-06-15 BR BRPI0512110-8A patent/BRPI0512110A/en not_active IP Right Cessation
- 2005-06-15 WO PCT/US2005/020911 patent/WO2006002038A2/en active Application Filing
- 2005-06-15 HU HUE15153954A patent/HUE036894T2/en unknown
- 2005-06-15 EP EP05760552A patent/EP1765417A4/en not_active Withdrawn
- 2005-06-15 KR KR1020077000993A patent/KR20070028537A/en not_active Application Discontinuation
- 2005-06-15 AU AU2005257938A patent/AU2005257938B2/en not_active Ceased
- 2005-06-15 MX MXPA06014915A patent/MXPA06014915A/en active IP Right Grant
- 2005-06-15 ES ES15153954.1T patent/ES2645158T3/en active Active
- 2005-06-15 JP JP2007516632A patent/JP4942646B2/en active Active
- 2005-06-15 US US11/153,054 patent/US20060014713A1/en not_active Abandoned
- 2005-06-15 EE EEP200700003A patent/EE200700003A/en unknown
- 2005-06-15 RU RU2007101039/15A patent/RU2007101039A/en not_active Application Discontinuation
- 2005-09-22 US US11/234,396 patent/US7405285B2/en not_active Expired - Fee Related
-
2006
- 2006-12-11 IL IL179973A patent/IL179973A0/en unknown
- 2006-12-29 MA MA29600A patent/MA28976B1/en unknown
-
2007
- 2007-01-12 HR HR20070012A patent/HRP20070012A2/en not_active Application Discontinuation
- 2007-01-15 LV LVP-07-03A patent/LV13641B/en unknown
- 2007-01-15 NO NO20070263A patent/NO20070263L/en not_active Application Discontinuation
- 2007-10-23 US US11/876,913 patent/US20080193437A1/en not_active Abandoned
-
2009
- 2009-09-23 US US12/565,151 patent/US8420615B2/en active Active
-
2015
- 2015-12-09 HK HK15112153.1A patent/HK1211179A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1765417A4 (en) | 2009-03-25 |
EP2901856B1 (en) | 2017-08-09 |
KR20070028537A (en) | 2007-03-12 |
MXPA06014915A (en) | 2007-08-20 |
EP1765417A2 (en) | 2007-03-28 |
MA28976B1 (en) | 2007-11-01 |
US20060014713A1 (en) | 2006-01-19 |
BRPI0512110A (en) | 2007-10-23 |
CA2570786C (en) | 2013-05-28 |
LV13641B (en) | 2008-07-20 |
JP2008502688A (en) | 2008-01-31 |
WO2006002038A3 (en) | 2008-07-17 |
CA2570786A1 (en) | 2006-01-05 |
EP2901856A1 (en) | 2015-08-05 |
US7405285B2 (en) | 2008-07-29 |
NZ552522A (en) | 2009-04-30 |
US8420615B2 (en) | 2013-04-16 |
IL179973A0 (en) | 2007-05-15 |
US20080193437A1 (en) | 2008-08-14 |
US20100166736A1 (en) | 2010-07-01 |
ES2645158T3 (en) | 2017-12-04 |
JP4942646B2 (en) | 2012-05-30 |
HUE036894T2 (en) | 2018-08-28 |
RU2007101039A (en) | 2008-07-20 |
HRP20070012A2 (en) | 2007-10-31 |
EE200700003A (en) | 2007-06-15 |
AU2005257938A1 (en) | 2006-01-05 |
AU2005257938B2 (en) | 2010-11-11 |
NO20070263L (en) | 2007-03-09 |
WO2006002038A2 (en) | 2006-01-05 |
US20070179103A1 (en) | 2007-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211179A1 (en) | Immunostimulatory oligonucleotide multimers | |
TWI365191B (en) | Vaccine | |
EP1865925A4 (en) | Buccal delivery system | |
HK1082029A1 (en) | Blower system | |
GB0409940D0 (en) | Vaccine | |
PT1907574E (en) | Oligonucleotides | |
IL173921A0 (en) | Vaccine | |
GB0329146D0 (en) | Vaccine | |
GB0411150D0 (en) | Vaccine | |
HU3357U (en) | Cushion | |
GB0305794D0 (en) | Vaccine | |
GB0330079D0 (en) | Vaccine | |
GB0413510D0 (en) | Vaccine | |
GB0305793D0 (en) | Vaccine | |
GB0426188D0 (en) | DNA repeats | |
GB0412407D0 (en) | Vaccine | |
GB0428381D0 (en) | Vaccine | |
GB2419271B (en) | Footwear comprising gripping means | |
AP2709A (en) | An anti-theileriosis vaccine | |
GB0406598D0 (en) | Vaccine | |
GB0419918D0 (en) | Vaccine | |
GB0514898D0 (en) | Introduction system | |
GB0417107D0 (en) | Genes II | |
GB0301459D0 (en) | Microrna | |
GB0317991D0 (en) | Microrna |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230615 |